{"product_id":"bjdx-marketing-mix","title":"(BJDX) Bluejay Diagnostics, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Bluejay Diagnostics, Inc. 4P's Marketing Mix Analysis explains the company’s product (diagnostic tests and devices), how they’re priced, distributed, and promoted, and shows a real preview of the structured analysis on this page. Purchase the full version to receive the complete, ready-to-use marketing mix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSymphony platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics’ core product is the Symphony platform, which pairs a benchtop analyzer with single-use cartridges for faster, more automated diagnostic testing. In its 4P mix, the product is aimed at reducing manual steps and shortening turnaround time in near-patient settings. Bluejay has said Symphony is its main commercial focus, so product execution is central to the company’s value story.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWhole-blood analyzer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc.'s Symphony analyzer processes whole blood directly, so it skips lab-style sample prep and fits point-of-care use. It isolates biomarkers and sets up immunoassays with non-contact centrifugal force, which helps reduce handling steps and keeps the workflow compact. That design matters for fast testing in small clinical settings where space, speed, and simple use are key.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePre-loaded cartridge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Symphony Cartridge comes pre-loaded with key reagents and components, so users skip manual setup steps. That lowers handling time and helps keep each test run more standardized. For Bluejay Diagnostics, Inc., this design supports more consistent results and a simpler workflow in near-patient testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eALLEREYE test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALLEREYE is Bluejay Diagnostics, Inc.'s on-site test for allergic conjunctivitis, built for rapid use at the point of care. It broadens Bluejay beyond the Symphony platform and supports a faster, more convenient diagnostic workflow. For the 2025\/2026 period, Bluejay has not publicly reported product-level ALLEREYE revenue, so its value is still tied to development and launch execution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOn-site allergic conjunctivitis test\u003c\/li\u003e\n\u003cli\u003eRapid-use, point-of-care positioning\u003c\/li\u003e\n\u003cli\u003eExpands beyond Symphony platform\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIL-6 and cardiac pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc. is building Symphony IL-6 tests for critical care monitoring, plus assays for myocardial infarction and congestive heart failure, so its pipeline sits squarely in high-acuity care. IL-6 helps track inflammation fast, which matters in sepsis and ICU cases, while cardiovascular testing addresses large, urgent pools of need: about 805,000 U.S. heart attacks and 6.7 million adults with heart failure each year. That mix supports a product set aimed at speed, triage, and repeat testing in hospitals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets ICU and emergency settings.\u003c\/li\u003e\n\u003cli\u003eSupports fast inflammation monitoring.\u003c\/li\u003e\n\u003cli\u003eAddresses large cardiac disease volumes.\u003c\/li\u003e\n\u003cli\u003eFits high-need, high-frequency testing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBluejay Diagnostics Bets on Symphony and Critical-Care POC Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc.'s product mix centers on Symphony: a whole-blood analyzer plus single-use cartridges for point-of-care testing, with ALLEREYE extending the platform into allergic conjunctivitis. The pipeline also targets IL-6 and cardiac assays, aimed at ICU and ED use where rapid triage matters.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003e2025\/2026 note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSymphony\u003c\/td\u003e\n\u003ctd\u003eWhole-blood POC\u003c\/td\u003e\n\u003ctd\u003eMain focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALLEREYE\u003c\/td\u003e\n\u003ctd\u003eAllergic conjunctivitis\u003c\/td\u003e\n\u003ctd\u003eNo revenue reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIL-6\/cardiac\u003c\/td\u003e\n\u003ctd\u003eCritical care\u003c\/td\u003e\n\u003ctd\u003eIn development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific breakdown of Bluejay Diagnostics, Inc.’s Product, Price, Place, and Promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTurns Bluejay Diagnostics’ 4Ps into a quick, structured snapshot that eases analysis and speeds team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources to verify Bluejay Diagnostics’ market, pricing, and competitive assumptions for faster, defensible decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActon, Massachusetts HQ\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc. is headquartered in Acton, Massachusetts, and that site serves as its main operating base for corporate, development, and administrative work. As of its latest reported filings, the Company reported $0.0 million in product revenue for fiscal 2025, so the Acton HQ remains a lean control center rather than a large manufacturing hub. That setup supports tight oversight of R\u0026amp;D, finance, and management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePoint-of-care setting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc. built Symphony for point-of-care use, so testing happens near the patient instead of a central lab. That shortens the path from sample to result and helps clinicians act faster in urgent care settings. In 2025, Bluejay Diagnostics, Inc. remained pre-revenue, so the point-of-care setting is central to its market push.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCritical care environments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSymphony IL-6 is intended for critical care use, so Bluejay Diagnostics, Inc. should place it in hospital-centered channels. The best fit is high-acuity areas like ICU and emergency care, where clinicians need fast results to support time-sensitive decisions. That makes the place strategy dependent on direct hospital adoption, not retail or home settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEye-care sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALLEREYE fits ophthalmology and eye-care sites because it supports on-site screening for allergic conjunctivitis, helping clinics sort patients fast before a full exam. In eye-care settings, quick triage matters, since allergic conjunctivitis is one of the most common eye-allergy complaints seen in practice.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOn-site screening for allergic conjunctivitis\u003c\/li\u003e\n\u003cli\u003eFits clinics and ophthalmology workflows\u003c\/li\u003e\n\u003cli\u003eHelps speed early patient triage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHospital and clinical channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc.’s future tests fit best in hospital and clinical diagnostic channels, where doctors order cardiovascular and inflammatory testing at the point of care. U.S. hospitals number about 6,100, so the main route to market is institutional care, not retail labs. \u003c\/p\u003e\n\u003cp\u003eThat channel matters because these tests can support faster triage in emergency and inpatient settings, where every hour counts. For Bluejay Diagnostics, Inc., hospital adoption can drive the earliest revenue and strongest clinical validation. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBest fit: hospital labs and clinics\u003c\/li\u003e\n\u003cli\u003eFastest use: emergency and inpatient care\u003c\/li\u003e\n\u003cli\u003eMarket focus: institutional buyers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBluejay Diagnostics Targets Hospitals, Not Homes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc. uses Acton, Massachusetts as its base for corporate and R\u0026amp;D work, while its tests are built for hospital and clinic point-of-care use. Symphony IL-6 and ALLEREYE fit ICU, emergency, and ophthalmology workflows, not retail or home channels. With 2025 product revenue at $0.0 million, place strategy still centers on institutional adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eActon HQ\u003c\/td\u003e\n\u003ctd\u003eOps, R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$0.0m revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eCore channel\u003c\/td\u003e\n\u003ctd\u003e~6,100 U.S. hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eBluejay Diagnostics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Bluejay Diagnostics 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises. It’s the full, editable document, ready to use for strategy, presentations, or due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics uses investor communications to share company news, development milestones, and strategic updates, which is standard for a pre-commercial diagnostics company. In its 2025 filings, the company still had no commercial product revenue, so investor updates are a key way to explain progress and funding needs. This helps the market track trial timelines, regulatory steps, and capital use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePress releases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics uses press releases to flag Symphony and ALLEREYE progress, so the market can track assay, platform, and regulatory steps as they land. These updates help build awareness around two pipeline assets and keep investors and partners aligned on development timing. For a micro-cap biotech, that steady news flow can matter as much as cash, since credibility often drives follow-on interest and deal access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical data messaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics’ promotion leans on clinical utility, with IL-6, allergic conjunctivitis, and cardiac test messaging aimed at unmet care needs. Sepsis causes about 11 million deaths a year worldwide, so fast IL-6 data matters. By tying the brand to real medical use cases, the company sells performance, not just the device.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific and industry visibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc. should use conferences and scientific venues to show technical proof, because medtech buyers trust peer-reviewed and clinician-led evidence. In diagnostics, 2025 conference visibility can matter as much as ad spend, since medical affairs and KOL outreach help explain assay performance, workflow fit, and clinical use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse ASCP, AACC, and ESC-style venues\u003c\/li\u003e\n\u003cli\u003eShow data on sensitivity and turnaround time\u003c\/li\u003e\n\u003cli\u003eTarget clinicians and lab leaders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCorporate website and filings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc. uses its corporate website and SEC filings as core promotion tools, giving investors product details, development status, and corporate updates in one place. For a pre-commercial company, these channels matter because they build awareness and transparency more than ad spend or broad media campaigns. The latest filings also frame risk, cash use, and milestones clearly for shareholders.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProduct status and pipeline updates\u003c\/li\u003e\n\u003cli\u003eSEC disclosures and risk factors\u003c\/li\u003e\n\u003cli\u003eInvestor awareness and trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBluejay Diagnostics Drives 2025 Awareness Through Pipeline and Clinical Milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics’ promotion in 2025 centered on investor updates, press releases, and scientific conference visibility, since it had no commercial product revenue. It used these channels to highlight Symphony and ALLEREYE progress, regulatory steps, and clinical use cases such as IL-6 and allergic conjunctivitis. This keeps shareholders, clinicians, and partners aligned on milestones and funding needs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestor updates\u003c\/td\u003e\n\u003ctd\u003eNo product revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePress releases\u003c\/td\u003e\n\u003ctd\u003ePipeline and regulatory news\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003eClinical proof and KOL reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo public list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc. has not publicly disclosed a standard list price for Symphony or ALLEREYE, so pricing is company-controlled rather than retail posted. That fits clinical diagnostics, where pricing often depends on contract terms, reimbursement, and test volume. As of the latest public filings, no fixed 2026 list price has been published.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics sells to hospitals, clinics, and labs, so its price is usually negotiated, not posted to consumers. In Bluejay Diagnostics' 2025 filing, it still did not disclose a public list price or product revenue, which shows contract terms, volume, and reagent commitments drive the final rate. For healthcare buyers, that means unit economics depend on throughput and service terms, not sticker price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnalyzer plus cartridge model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc. uses a capital equipment plus consumables price mix: the analyzer is the platform device, while cartridges are the recurring test input. That setup can support repeat sales and steadier cash flow after each analyzer placement. It also matters because cartridge-led diagnostics models can lift lifetime customer value versus a one-time hardware sale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReimbursement-linked economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc. pricing is best viewed through reimbursement, not shelf price: in diagnostics, payer coverage and CPT\/HCPCS payment rules often decide whether a test is used. That means Bluejay’s value depends on clinical adoption, coverage, and lab workflow fit, so pricing is tied to medical use and reimbursement acceptance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage drives test uptake.\u003c\/li\u003e\n\u003cli\u003ePayer acceptance sets realized price.\u003c\/li\u003e\n\u003cli\u003eClinical utility supports reimbursement.\u003c\/li\u003e\n\u003cli\u003eAdoption matters more than list price.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial launch pending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc. has several products still in development or early expansion, so a finalized market price has not been set for a commercial launch. As of July 2026, public price transparency remains limited, which makes a firm 2025\/2026 pricing call impossible from disclosed data alone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLaunch pricing not yet disclosed\u003c\/li\u003e\n\u003cli\u003eStill in development or expansion\u003c\/li\u003e\n\u003cli\u003ePublic transparency remains limited\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBluejay’s pricing stays private, with reimbursement and volume setting the real price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBluejay Diagnostics, Inc. does not disclose a public list price for Symphony or ALLEREYE, so pricing is negotiated with hospitals, clinics, and labs. In the 2025 filing, no product revenue or fixed 2026 price was disclosed, which shows reimbursement, volume, and contract terms set realized price.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eBluejay Diagnostics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic list price\u003c\/td\u003e\n\u003ctd\u003eNot disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 product revenue\u003c\/td\u003e\n\u003ctd\u003eNot disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice driver\u003c\/td\u003e\n\u003ctd\u003eReimbursement and volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234116870409,"sku":"bjdx-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bjdx-marketing-mix.webp?v=1785713086","url":"https:\/\/dcfanalyst.com\/products\/bjdx-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}